在心力衰竭中SUMO1依赖SERCA2a的调制
Changwon Kho1, Ahyoung Lee, Dongtak Jeong
1Cardiovascular Research Center, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1030, New York, New York 10029, USA.
Nature
|September 9, 2011
概括
SERCA2a (sarco/endoplasmic reticulum calcium ATPase) 的SUMOylation对于心脏功能至关重要,因为它可以促进心脏的运转. 通过稳定SERCA2a,恢复SUMO1水平在心力衰竭模型中改善了心脏功能.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 运输的ATPase ATP2A2 (SERCA2a) 对于心脏刺激-收缩合至关重要.
- 减少SERCA2a表达和活性是心力衰竭的特征.
- 恢复SERCA2a的基因治疗改善了心力衰竭中的心脏功能.
研究的目的:
- 为了研究小型无素相关修饰剂 (SUMO) 结合在SERCA2a调节中的作用.
- 为了确定SUMOylation是否影响SERCA2a的活动,稳定性和心脏功能.
- 探索SUMO1作为心力衰竭的潜在治疗点.
主要方法:
- 在SERCA2a (lysines 480和585) 上确定了SUMOylation位点.
- 在失败的心脏中评估SERCA2a SUMOylation水平.
- 利用腺相关病毒 (AAV) 介导的基因传递来恢复心力衰竭模型中的SUMO1.
- 使用小毛RNA (shRNA) 来降低SUMO1.
- 评估心脏功能,收缩性和Ca2+) 在体外和体内处理.
主要成果:
- 在K480/K585的SERCA2aSUMOylation对于其ATPase活性和稳定性至关重要.
- 在失败的心脏中,SUMO1水平和SERCA2a SUMOylation 降低.
- 在心力衰竭的小鼠模型中,AAV介导的SUMO1输送改善了心脏功能和SERCA2a丰富度,与SERCA2a基因输送相似.
- 过度表达SUMO1增强了心肌细胞收缩性和Ca2+) 衰变.
- 降低SUMO1调节加剧了压力过载引起的心脏功能障碍,并降低了SERCA2a功能.
结论:
- SUMOylation是一种关键的翻译后修饰,调节SERCA2a的功能和稳定性.
- 恢复SUMO1水平,通过保持SERCA2a功能,为心力衰竭提供了一种新的治疗策略.
- 准SUMOylation通路为开发新型心力衰竭治疗提供了一个有希望的途径.
相关概念视频
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...